Bioniks is developing a unique clinical movement analysis framework to provide objective and accurate physical assessment in clinic, as well as applications outside of clinic, such as athletic training and personal fitness. Our technology features 3D depth cameras and marker-less motion capture, integrated with an intuitive user interface and streamlined data processing, to bring high-fidelity motion analysis to patient outcomes assessment. Members of the Bioniks team have extensive research experience in musculoskeletal modeling and applied clinical research. Bioniks has several ongoing collaborations with research institutions for continuous technology development and clinical validation. Bioniks' proprietary technology integrates a biomechanical modeling approach that uniquely filters the kinematic motion to improve the accuracy and reduce the jitter that is typically associated with the depth camera body tracking. Digital tools provided by Bioniks are based on physiologically accurate motion tracking, providing data for assessment of full-body movement patterns and patient-specific biomechanics.

Our technology is designed to provide a quantitative assessment of physical impairments, including knee, spine, and shoulder conditions. Bioniks aims to fill a critical gap among clinical tools for patient functional assessment by enabling providers to easily quantify patient-specific biomechanics and track patient progress.

Our ongoing research advances the quantitative assessment of patient motion through kinematic analysis and ultimately computing patient-specific parameters related to joint loading using musculoskeletal dynamics models. These analyses would allow the practitioner and patient to track the recovery process through direct observation of relevant functional parameters.

Recently, Bioniks has released its first product, the Kinetigram cloud-connected platform, which includes an upper extremity module for the shoulder assessment based on the kinematic analysis of motion data from a depth camera. Current release (Version 2) has been FDA-registered and CE-marked and is currently being used in an international clinical trial.